ArmaGen announces FDA acceptance of IND application for AGT-182 for the treatment of MPS II

ArmaGen announced that the FDA accepted the IND application for AGT-182 for the treatment of MPS II. A Phase 1 clinical trial is expected to begin in the first quarter of 2015. Read the full press release.

This entry was posted in News. Bookmark the permalink.

Comments are closed.